Roche abandons development of an experimental cholesterol drug as a late-
stage trial showed it wasn’t working, FDA staff members question the benefits of an arthritis drug from Pfizer and Novo Nordisk steps up research on diabetes
with an ambitious eye toward a difficult goal—a cure